Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
1.80
-0.03 (-1.64%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.80 - 1.84
52 week 1.43 - 4.24
Open 1.83
Vol / Avg. 566,372.00/1.31M
Mkt cap 221.04M
P/E     -
Div/yield     -
EPS -0.70
Shares 121.46M
Beta 1.13
Inst. own 19%
Apr 14, 2015
Galena Biopharma Inc at Needham Healthcare Conference - 10:40AM EDT - Add to calendar
Mar 9, 2015
Galena Biopharma Inc at ROTH Conference - 11:00AM EDT - Add to calendar
Mar 5, 2015
Q4 2014 Galena Biopharma Inc Earnings Call - 5:00PM EST - Add to calendar
Mar 5, 2015
Q4 2014 Galena Biopharma Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 10, 2015
Galena Biopharma Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 20, 2015
Galena Biopharma Inc at Noble Financial Equity Conference
Dec 10, 2014
Galena Biopharma Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -381.05% -3083.15%
Operating margin -778.46% -1397.91%
EBITD margin - -1342.50%
Return on average assets -30.99% -107.27%
Return on average equity -83.69% -455.85%
Employees 60 -
CDP Score - -

Address

SUITE 270, 4640 SW MACADAM AVENUE
PORTLAND, OR 97239
United States - Map
+1-855-8554253 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. (Galena) is a biopharmaceutical company. The Company is developing and commercializing oncology therapeutics that address medical needs across the spectrum of cancer care. Galena�s development portfolio ranges from mid- to late-stage clinical assets, including an immunotherapy program led by NeuVax (nelipepimut-S) was in an international, Phase III clinical trial as of December 8, 2014. The Company�s commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. Its other pipeline products include GALE-301 (Folate Binding Protein (FBP)) and GALE-401 (Anagrelide CR). GALE-301 is immunogenic and can stimulate cytotoxic T lymphocyte (CTLs) to recognize and destroy FBP-expressing cancer cells. GALE-401 contains the active ingredient anagrelide, the United States Food and Drug Administration FDA-approved product.

Officers and directors

Sanford J. Hillsberg J.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Ryan M. Dunlap Chief Financial Officer, Vice President, Secretary
Age: 44
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
Irving M. Einhorn Director
Age: 72
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A Kriegsman Independent Director
Age: 72
Bio & Compensation  - Reuters